ĐÁNH GIÁ HIỆU QUẢ CHUYỂN ĐỔI HUYẾT THANH CỦA TENOFOVIR DISOPROXIL FUMARATE VÀ TENOFOVIR ALAFENAMIDE Ở BỆNH NHÂN VIÊM GAN VI RÚT B MẠN

Abstract

Objective: To evaluate the seroconversion efficacy of Tenofovir disoproxil fumarate (TDF) and Tenofovir alafenamide (TAF) in patients with chronic viral hepatitis B. Methods: A descriptive cross-sectional study was conducted in 111 chronic hepatitis B outpatients with positive HbeAg treated with TDF 300mg (74 patients) or TAF 25mg (37 patients) at the Ho Chi Minh City University Medical Center from January 2017 to December 2020. Results: In both groups of patients treated with TAF or TDF, the percentage of men was dominant (2.7/1); the mean age in the two groups was 41 and 37 years old, respectively; Mean ALTs were 27 UI / L and 48 UI / L; mean HBV DNA load at initiation of treatment was 7.85 and 7.87 log₁₀UI /ml, respectively. After 48 weeks of treatment, the rate of HBeAg loss of the 2 groups were 13.51% and 14.86%, respectively (p = 0.84); The rate of HBV DNA negative in the group of patients treated with TAF and TDF  was 67.00% and 58.10%, respectively, p = 0.33; The rate of normal ALT attainment of the 2 groups was 54.54% and 33.33%, respectively, p = 0.20. Conclusion: The study results showed that after 48 weeks, the treatment effect was similar between the two groups of patients treated with TAF or TDF in the rate of achieving negative HBV DNA load, HBeAg loss and normal ALT attainment.